Latest News

Additional FDA Approval for Olaparib Tablets in Ovarian Cancer

Additional FDA Approval for Olaparib Tablets in Ovarian Cancer

Patients in the olaparib arm experienced a 70% reduction in the risk of disease progression or death vs placebo.

Besponsa Approved for B-cell Acute Lymphoblastic Leukemia

Besponsa Approved for B-cell Acute Lymphoblastic Leukemia

The FDA granted approval to inotuzumab ozogamicin for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.

Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer

Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer

Atezolizumab monotherapy has a good overall response rate (ORR) and favorable safety profile in patients with advanced PD-L1 expressing non-small cell lung cancer (NSCLC).

NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis

NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis

Compared with ALK¬-positive patients, participants with ROS1 rearrangements were less likely to present with extrathoracic and brain metastases.

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma

At the median follow-up 22.9 months, 56.3% of patients in the BV arm achieved a significantly superior objective global response lasting at least 4 months vs 12.5% of patients in the IC arms.

Statin-use May Decrease Mortality Risk in Prostate Cancer

Statin-use May Decrease Mortality Risk in Prostate Cancer

Patients who were diagnosed early on in the study, or who received endocrine therapy or radical prostatectomy, exhibited a lower HR for mortality vs other patients with PC.

Sequencing 5 CTCs May Effectively Guide Cancer Treatment

Sequencing 5 CTCs May Effectively Guide Cancer Treatment

Given the comprehensiveness of LFR, the driver mutations and tissues of origin detected via this method may better guide treatment than most available gene panel-tests.

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.

Alternative Medicine May Lead to Worse Outcomes Among Patients With Cancer

Alternative Medicine May Lead to Worse Outcomes Among Patients With Cancer

Patients with breast or lung cancer, fewer comorbidities, more advanced cancer, higher income and education, or who were younger or female were more likely to use AM.

Patients With Cancer Assess Physical Status Differently vs Caregivers

Patients With Cancer Assess Physical Status Differently vs Caregivers

Caregivers were also more likely to have greater care-related burden when patients reported requiring help with fewer IADLs than did the caregiver.

Ipatasertib May Prolong PFS in Triple-negative Breast Cancer

Ipatasertib May Prolong PFS in Triple-negative Breast Cancer

Researchers randomly assigned 124 patients to receive intravenous paclitaxel with ipatasertib or placebo.

Individualized Radiotherapy Effective in Liver Cancer

Individualized Radiotherapy Effective in Liver Cancer

The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.

Phase 1/2 Study of 6MHP Vaccine and Ipilimumab for Advanced Melanoma

Phase 1/2 Study of 6MHP Vaccine and Ipilimumab for Advanced Melanoma

Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.

Prostate Cancer: Metastasis-free Survival Is A Surrogate for OS

Prostate Cancer: Metastasis-free Survival Is A Surrogate for OS

Researchers evaluated data from patients with prostate cancer to determine whether MFS or DFS are valid surrogate markers for OS.

Obinutuzumab Plus CHOP Does Not Prolong PFS in DLBCL

Obinutuzumab Plus CHOP Does Not Prolong PFS in DLBCL

Researchers enrolled 1418 patients with previously untreated DLBCL and randomly assigned them to receive G-CHOP or R-CHOP.

Low-cost Liquid Biopsy for Epstein-Barr Virus Detects Nasopharyngeal Carcinoma

Low-cost Liquid Biopsy for Epstein-Barr Virus Detects Nasopharyngeal Carcinoma

Researchers analyzed participant plasma specimens to determine whether EBV presence could effectively predict asymptomatic, early nasopharyngeal carcinoma.

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.

Dexamethasone, Rituximab, and Cyclophosphamide Effective in Waldenström Macroglobulinemia

Dexamethasone, Rituximab, and Cyclophosphamide Effective in Waldenström Macroglobulinemia

In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters